Skeletal muscle mitochondrial (dys)function in humans: Relating macroscopic in vivo observations to mechanistic understanding at molecular scale

Skeletal muscle mitochondrial (dys)function in humans: Relating macroscopic in vivo observations to mechanistic understanding at molecular scale - systems biology of mitochondrial dysfunction

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39110

Enrollment

Registered

2011-11-16

Start date

2012-03-09

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

veroudering, mitochondriële myopathie aging diabetes

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All subjects: - written informed consent;Mitochondrial myopathy: - patients diagnosed with mitochondrial myopathy - Age: 18+;Type 2 diabetes: - patients diagnosed with Type 2 diabetes for at least 2 years - age: 18+ - BMI 26 - 42 kg/m2 - sedentary behaviour as confirmed by a questionnaire asking about physical activity levels - sex: male Elderly with sedentary lifestyle: - Age: 50 - 75 yrs - sedentary lifestyle as confirmed by a questionnaire asking about physical activity levels - sex: male ;Elderly with active lifestyle: - Age: 50 - 75 yrs - active lifestyle as confirmed by a questionnaire asking about physical activity levels - sex: male Control subjects: - Age: 20 - 30 yrs - BMI: 20 - 25 - Normally active lifestyle as confirmed by a questionnaire asking about physical activity levels - sex: male

Exclusion criteria

Exclusion criteria: All subjects: - pacemaker / implantable cardioverter defibrillator (ICD) - metal prostheses - implanted devices - vascular clips - profession (current of in the past) as welder or metalworker (risk of small metal fragments in eyes);- claustrophobia - use of oral anti-coagulants - use of inorganic nitrate - cardio-vascular disease (decompensatio cordis, agina pectoris, myocardial infarction of positive signs of cardiac ischaemia on the ECG during the incremental exercise test on the bicycle ergometer) - cerebro-vascular disease (CVA) - neurological diseases of deficits - vascular complications

Design outcomes

Primary

Measure	Time frame
Mitochondrial function will be assessed by 31P magnetic resonance spectroscopy (rate of PCr recovery after submaximal exercise) in M. vastus lateralis. Differences in molecular phenotype of the muscle cells will be obtained by analysis of muscle biopsy samples for: - State 3, 4, U respiration - Complex I, II, III, IV, ATPase, ANT, UCP3 content - Mitochondrial DNA copy number - Fiber type composition, muscle vascularisation	—

Measure

Time frame

Mitochondrial function will be assessed by 31P magnetic resonance spectroscopy (rate of PCr recovery after submaximal exercise) in M. vastus lateralis. Differences in molecular phenotype of the muscle cells will be obtained by analysis of muscle biopsy samples for: - State 3, 4, U respiration - Complex I, II, III, IV, ATPase, ANT, UCP3 content - Mitochondrial DNA copy number - Fiber type composition, muscle vascularisation

—

Secondary

Measure	Time frame
- VO2max en Qmax determined on calibrated bicycle ergometer - Relation between oxygen consumption and power output determined on calibrated bicycle ergometer	—

Countries

Netherlands

Outcome results